Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Maruzzo

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Frontiers in Oncology|June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2023
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO networkEmilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer|April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Frontiers in Oncology|June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2023
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO networkEmilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer|April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
Journal of Geriatric Oncology|August 13, 2025
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinomaVeronica Murianni, Marina Campione, Malvina Cremante, et al.
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Pageof 15